SEC Form 4 · accession 0001562180-18-000414
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mariam E Morris
Officer — Chief Financial Officer
Period of report
Jan 22, 2018
Accepted (ET)
Jan 24, 2018 · 12:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.21 | Jan 22, 2018 | A | 100,000 | A | — | Jan 21, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F11/4 of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining 3/4 of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 36 months beginning on 22-Jan-2018